Oct 7 (Reuters) – Maat Pharma SA: * MAAT PHARMA ANNOUNCES POSITIVE SECOND SAFETY INTERIM ANALYSIS FROM DSMB FOR PHASE 2B PHOEBUS TRIAL EVALUATING MAAT033 FOR PATIENTS RECEIVING ALLO-HSCT * MAAT PHARMA SA – MAAT033 SHOWS FAVORABLE SAFETY PROFILE AND TOLERABILITY
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
इंदौर [मध्य प्रदेश, भारत], 16 अगस्त: जब एक ही कक्षा के कई बच्चे पढ़ने में…
Yandina, Australia (dpa) – The last macadamia nuts of the season lie on the ground.…
इंदौर [मध्य प्रदेश, भारत], 16 अगस्त: जब एक ही कक्षा के कई बच्चे पढ़ने में…
Barcelona (dpa) – Climate change is hitting the cities of Europe hard and fast, with…
Berlin (dpa) – Ginger shots have been all the rage for years, whether for people…
Berlin (dpa) – Fans of cooking videos may have heard that special crunch when someone…